Arthritis Clinical Trials

Inclusion criteria :

Diagnosis of rheumatoid arthritis ≥ 3 months duration

Active disease defined as:

• at least 8/68 tender joints and 6/66 swollen joints,
• high sensitivity C-reactive protein (hs-CRP) > 6 mg/l,
• continuous treatment with MTX for at least 12 weeks prior to baseline visit and on stable dose for 6 weeks prior to screening visit

Part B only:

• Bone erosion based on documented X-ray prior to first study drug intake, or
• Cyclic Citrullinated Peptide (CCP) positive, or
• Rheumatoid Factor (RF) positive

Exclusion criteria:

Age <18 years or >75 years. Treatment with disease-modifying antirheumatic drugs (DMARDs) other than MTX within 4 weeks or 12 weeks prior to screening (depending on DMARDs).

Past history of non response to prior Tumor Necrosis Factor (TNF) or biologic treatment.

Any past or current biologic agents for the treatment of rheumatoid arthritis within 3 months.

Use of parenteral glucocorticoids or intraarticular glucocorticoids within 4 weeks prior to screening visit.

Use of oral glucocorticoid greater than 10mg/day or equivalent/day, or a change in dosage within 4 weeks prior to baseline visit.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.